← Eichor
Condition: Her2 Metastatic Breast Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her2 Metastatic Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Phase 1/Phase 2 · 10 location(s) · SynDevRx, Inc. · NCT05455619ctDNA-guided Treatment Decision-making
Phase 2 · 1 location(s) · Fudan University · NCT07394218Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
Phase 4 · 1 location(s) · Fudan University · NCT06230055RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT07030569Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
Phase 2 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT05770531Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
Phase N/A · 1 location(s) · Julia Foldi · NCT06666439A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2 · 13 location(s) · Processa Pharmaceuticals · NCT06568692Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
Phase N/A · 1 location(s) · Mayo Clinic · NCT04517838CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Phase 1 · 7 location(s) · University of Texas Southwestern Medical Center · NCT05029999Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Phase 2 · 1 location(s) · Dartmouth-Hitchcock Medical Center · NCT05933395A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With An
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT06827236Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and A
Phase 2 · 1 location(s) · University of Rochester · NCT04965064S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic
NA · 723 location(s) · SWOG Cancer Research Network · NCT03723928A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Phase 1/Phase 2 · 2 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06202261BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Sp
Phase 1/Phase 2 · 18 location(s) · Merck Sharp & Dohme LLC · NCT06686394Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Phase 1/Phase 2 · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04923542Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Canc
Phase 3 · 31 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07008976A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast C
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06957886A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire
Phase 1 · 4 location(s) · Genentech, Inc. · NCT07214662A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
Phase 3 · 70 location(s) · GeneQuantum Healthcare (Suzhou) Co., Ltd. · NCT07673029A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metasta
Phase 4 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06641544Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Phase 1/Phase 2 · 86 location(s) · Stemline Therapeutics, Inc. · NCT05386108A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid
Phase 1 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06503783Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastat
Phase 1/Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06167694Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT05530057VS-6766+Abema+Fulv in Met HR+/HER- BC
Phase 1/Phase 2 · 3 location(s) · Adrienne G. Waks · NCT05608252A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Parti
Phase 2 · 54 location(s) · Bayer · NCT06760819Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Phase 2 · 1 location(s) · University of Wisconsin, Madison · NCT04573231
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.